Matt Phipps

Stock Analyst at William Blair

(0.43)
# 4,121
Out of 4,966 analysts
21
Total ratings
33.33%
Success rate
-32.42%
Average return

Stocks Rated by Matt Phipps

Insmed
Aug 20, 2025
Initiates: Outperform
Price Target: n/a
Current: $136.10
Upside: -
MiNK Therapeutics
Jul 14, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $14.24
Upside: -
Jasper Therapeutics
Jul 7, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $2.80
Upside: -
Context Therapeutics
Apr 21, 2025
Initiates: Outperform
Price Target: n/a
Current: $0.84
Upside: -
Xencor
Apr 21, 2025
Initiates: Outperform
Price Target: n/a
Current: $8.13
Upside: -
Genmab
Mar 11, 2025
Upgrades: Outperform
Price Target: n/a
Current: $24.87
Upside: -
Keros Therapeutics
Dec 12, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $15.21
Upside: -
Upstream Bio
Nov 5, 2024
Initiates: Outperform
Price Target: n/a
Current: $17.13
Upside: -
Tenax Therapeutics
Sep 30, 2024
Initiates: Outperform
Price Target: n/a
Current: $5.92
Upside: -
Cullinan Therapeutics
Apr 15, 2024
Initiates: Outperform
Price Target: n/a
Current: $7.54
Upside: -
Downgrades: Market Perform
Price Target: n/a
Current: $47.18
Upside: -
Downgrades: Market Perform
Price Target: n/a
Current: $3.95
Upside: -
Initiates: Outperform
Price Target: n/a
Current: $22.72
Upside: -
Initiates: Outperform
Price Target: n/a
Current: $9.92
Upside: -
Upgrades: Outperform
Price Target: n/a
Current: $132.22
Upside: -
Initiates: Outperform
Price Target: n/a
Current: $65.84
Upside: -